| |
著者: Renan Bazuco Frittoli, Jéssica Fernandes Vivaldo, Lilian Tereza Lavras Costallat, Simone Appenzeller
雑誌名: J Transl Autoimmun. 2021;4:100106. doi: 10.1016/j.jtauto.2021.100106. Epub 2021 Jun 10.
Abstract/Text
Introduction: Gastrointestinal involvement is a common complain observed in 40-60% of systemic lupus erythematosus (SLE) patients. We performed a systematic review of clinically severe and potential life-threatening gastrointestinal manifestations and discuss clinical presentation, pathogenesis and treatment.
Methods: We performed a literature search in English literature using PubMed and Embase from 2000 to December 2020. The following MeSH terms: systemic lupus erythematosus, protein-losing enteropathy, ascites, pancreatitis, vasculitis, intestinal vasculitis, enteritis and diarrhea published in the English literature.
Results: We identified 141 studies (case reports, case series and cohort studies). The most frequent presenting symptoms are acute abdominal pain, nausea, and vomiting. Many of the manifestations were associated with disease activity. Histological features are rarely available, but both vasculitis and thrombosis have been described. There is no treatment guideline. The majority of patients were treated with corticosteroids and the most common immunososupressant were azathioprine, cyclophosphamide and mycophenolate.
Conclusion: Vasculitis and thrombosis may be responsible for severe life-threatening manifestations such as pancreatitis, protein loosing gastroenteritis, acalculous cholecistyitis and enteritis.
© 2021 The Authors. Published by Elsevier B.V.
PMID 34179742 J Transl Autoimmun. 2021;4:100106. doi: 10.1016/j.jtauto.2021.100106. Epub 2021 Jun 10.
|
